Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine

Completed

• Conditions: Other Abortion

• Registration Number: NCT02415894
• Lead Sponsor: Gynuity Health Projects

Brief Summary

The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Ukraine.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04
• Study First Submitted: 2015-04-02
• Study First Submitted QC: 2015-04-09
• Study First Posted: 2015-04-14
• Primary Completion: 2016-04
• Study Completion: 2016-04
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-21
• Last Update Posted: 2016-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 172

Inclusion Criteria

• Having an ongoing pregnancy of 13-22 weeks gestation
• Be willing to undergo surgical completion if necessary
• Have no contraindications to study procedures, according to provider
• Be willing and able to consent to participate in the study
• Be willing to follow study procedures

Exclusion Criteria

• Known allergy to mifepristone or misoprostol/prostaglandin
• Any contraindications to vaginal delivery, including placenta previa
• Unable to provide consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of successful abortion	15 hours after start of misoprostol induction

Trial Locations

Locations (3)

Poltava City Maternity Hospital; 🇺🇦 Poltava, Ukraine

Vinnitsa Regional Hospital; 🇺🇦 Vinnitsa, Ukraine

Odessa Regional Hospital; 🇺🇦 Odessa, Ukraine